Mavyret™ (glecaprevir/pibrentasvir) – New drug approval

- On August 3, 2017 the FDA announced the approval of AbbVie's Mavyret (glecaprevir/pibrentasvir), for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

- An estimated 2.7 – 3.4 million Americans are chronically infected with HCV. Approximately 75% of Americans with HCV have genotype 1; 20 – 25% have genotypes 2 or 3; and a small number of patients are infected with genotypes 4, 5, or 6.

    — Additionally, HCV is common among individuals with severe chronic kidney disease (CKD), with more than 500,000 people having both chronic HCV and CKD.

- Mavyret is a fixed-dose combination containing an NS3/4A protease inhibitor (glecaprevir) and an NS5A inhibitor (pibrentasvir).

- The safety and efficacy of Mavyret were evaluated in approximately 2,300 adults with genotype 1, 2, 3, 4, 5, or 6 HCV infection without cirrhosis or with mild cirrhosis.

    — The trials demonstrated that 92% – 100% of patients who received Mavyret for 8, 12, or 16 weeks had no detectable virus in the blood 12 weeks after completing treatment.

- Mavyret carries a boxed warning regarding the risk of hepatitis B virus (HBV) reactivation in patients co-infected with HCV and HBV.

- Mavyret is contraindicated in patients with severe hepatic impairment (Child-Pugh C), and with use of atazanavir or rifampin.

- The other warning and precaution of Mavyret is the risk of reduced therapeutic effect due to concomitant use of Mavyret with carbamazepine, efavirenz-containing regimens, or St. John's Wort.

- The most common adverse reactions (> 10%) with Mavyret use were headache and fatigue.

- The recommended dose of Mavyret is 3 tablets (total daily dose: 300 mg glecaprevir/ 120 mg pibrentasvir) given orally once daily.

    — All patients should be tested for evidence of current or prior HBV infection before initiating treatment with Mavyret.
    — Mavyret is not recommended in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C).
    — The recommended treatment duration is based on the patient population in HCV mono-infected and human immunodeficiency virus type 1 (HIV-1)/HCV co-infected patients with compensated liver disease (with or without cirrhosis) and with or without renal impairment, including patients receiving dialysis. Refer to the tables below.

Treatment-Naïve Patients

HCV genotype	No cirrhosis	Compensated cirrhosis (Child-Pugh A)
1, 2, 3, 4, 5, or 6	8 weeks	12 weeks

Continued . . .

Treatment-Experienced Patients

HCV genotype	Patients previously treated with a regimen containing:	No cirrhosis	Compensated cirrhosis (Child-Pugh A)
1	An NS5A inhibitor* without prior treatment with an NS3/4A protease inhibitor	16 weeks	16 weeks
	An NS3/4A protease inhibitor† without prior treatment with an NS5A inhibitor	12 weeks	12 weeks
1, 2, 4, 5, or 6	PRS‡	8 weeks	12 weeks
3	PRS‡	16 weeks	16 weeks

* In clinical trials, patients were treated with prior regimens containing ledipasvir and sofosbuvir or daclatasvir with pegylated interferon and ribavirin.
† In clinical trials, patients were treated with prior regimens containing simeprevir and sofosbuvir, or simeprevir, boceprevir, or telaprevir with pegylated interferon and ribavirin.
‡ PRS = prior treatment experience with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A protease inhibitor or NS5A inhibitor.

- The wholesale acquisition cost for Mavyret ranges from $26,400 for 8 weeks of treatment to $52,800 for 16 weeks of treatment.

- AbbVie plans to launch Mavyret as soon as possible. Mavyret will be available as 4-week and 8-week cartons. Each carton contains seven daily dose wallets consisting of three 100 mg/40 mg glecaprevir/pibrentasvir tablets per wallet.